Este ensayo se realiza en África, Asia, Europa, América del Norte y América del Sur. El objetivo del ensayo es comparar el efecto de la dosis semanal (OW) de semaglutida subcutánea (1,0 mg) versus la dosis diaria de canagliflozina oral (300 mg) sobre el control glucémico en sujetos con diabetes tipo 2 (T2D) que reciben tratamiento de base con metformina.
Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
Buenos Aires, Argentina
CABA, Argentina
CABA, Argentina
Rosario, Argentina
Salta, Argentina